Checkmate Pharmaceuticals, Inc. (CMPI) 10K Annual Reports & 10Q SEC Filings

Cover Page - USD ($)	12 Months Ended
Cover Page - USD ($)	Dec. 31, 2021	Mar. 29, 2022	Jun. 30, 2021
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Document Annual Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Entity Registrant Name	Checkmate Pharmaceuticals, Inc.
Entity Central Index Key	0001651431
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Incorporation, State or Country Code	DE
Entity Address, State or Province	MA
Title of 12(b) Security	Common Stock
Trading Symbol	CMPI
Security Exchange Name	NASDAQ
Entity Public Float			$ 124,028,535
Entity Common Stock, Shares Outstanding		21,630,627
ICFR Auditor Attestation Flag	false
Entity File Number	001-39425
Entity Address, Address Line One	245 Main Street
Entity Address, Address Line Two	2nd Floor
Entity Address, City or Town	Cambridge
Entity Address, Postal Zip Code	02142
Entity Tax Identification Number	36-4813934
City Area Code	617
Local Phone Number	682-3625
Auditor Name	KPMG LLP
Auditor Firm ID	185
Auditor Location	Boston, Massachusetts

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/1651431/000119312522088386/d275568d10k.htm

View differences made from one year to another to evaluate Checkmate Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Checkmate Pharmaceuticals, Inc..

Continue

Assess how Checkmate Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Checkmate Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter by Sentiment:

All

Positive

Negative

Filter by Category:

All

Legal

Financial

Revenue

Other

Filter by Subcategory:

All

Expense

Cash Flow

Product

Income

Other

Inside Checkmate Pharmaceuticals, Inc.'s 10-K Annual Report:

Legal - Other Highlight
We also anticipate that we will continue to experience an increase in accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company.

Financial - Expense Highlight
We expect to continue to incur significant expenses and to increase operating losses for at least the next several years.
Financial - Cash Flow Highlight
We have incurred recurring losses and had negative operating cash flows since inception and our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of vidutolimod or any other products we acquire or develop.
Financial - Expense Highlight
Funding Requirements We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials for vidutolimod and any other product candidates that we may develop or acquire in the future.
Financial - Expense Highlight
Milestone payments under license agreements are accrued and a corresponding expense is recognized in the period in which the milestone is determined to be probable of achievement and the related amount is reasonably estimable.
Financial - Expense
In addition, as we advance...Read more
Revenue - Product
If we raise additional funds...Read more
Revenue - Product
If we raise additional funds...Read more
Financial - Expense
Inflation generally affects us by...Read more
Financial - Expense
As a result, we expect...Read more
Financial - Cash Flow
Cash Flows The following table...Read more
Financial - Expense
Such amounts are expensed as...Read more
Other - Other
The financial terms of these...Read more
Financial - Expense
We recognize external development costs...Read more
Financial - Expense
This process involves reviewing open...Read more
Other - Other
We may be unable to...Read more
Financial - Expense
Additionally, if we believe a...Read more
Other - Other
In August 2020, we completed...Read more
Financial - Expense
The increase of approximately $19.1...Read more
Financial - Shares
In connection with the IPO,...Read more
Other - Other
Although we do not expect...Read more
Financial - Expense
There may be instances in...Read more
Financial - Income
Interest Income available-for-sale Income Taxes...Read more
Financial - Income
Other income (expense), net available-for-sale...Read more
Financial - Expense
We anticipate that our general...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Checkmate Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Ticker: CMPI
CIK: 1651431
Form Type: 10-K Annual Report
Accession Number: 0001193125-22-088386
Submitted to the SEC: Tue Mar 29 2022 7:04:18 PM EST
Accepted by the SEC: Wed Mar 30 2022
Period: Friday, December 31, 2021
Industry: Biological Products No Disgnostic Substances